Ultragenyx Pharmaceutical (RARE) Equity Average (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Equity Average data on file, last reported at -$158.0 million in Q1 2026.

• Quarterly Equity Average fell 179.2% year-over-year to -$158.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$158.0 million (down 179.2% YoY) and the FY2025 annual result came in at $87.5 million, down 66.98% from the prior year.
• Equity Average fell to -$158.0 million in Q1 2026 per RARE's latest filing, from -$35.4 million in the prior quarter.
• Across five years, Equity Average topped out at $859.5 million in Q1 2022 and bottomed at -$158.0 million in Q1 2026.
• The 5-year median for Equity Average is $207.6 million (2024), against an average of $276.1 million.
• The widest annual swing landed in 2024, when Equity Average surged 384.77%; it then slumped 179.2% in 2026.
• Tracing RARE's Equity Average over 5 years: stood at $410.4 million in 2022, then plunged by 62.63% to $153.4 million in 2023, then surged by 96.22% to $300.9 million in 2024, then sank by 111.77% to -$35.4 million in 2025, then tumbled by 346.07% to -$158.0 million in 2026.
• Per Business Quant, the three latest RARE Equity Average figures stand at -$158.0 million (Q1 2026), -$35.4 million (Q4 2025), and $80.2 million (Q3 2025).

Peer Comparison